|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 317.74 USD | +0.11% |
|
-3.68% | +21.91% |
| Dec. 12 | FDA Approves Amgen's Uplizna (inebilizumab-cdon) for Generalized Myasthenia Gravis | CI |
| Dec. 12 | Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating | MT |
| Capitalization | 171B 146B 136B 128B 236B 15,497B 258B 1,589B 616B 7,305B 642B 628B 26,651B | P/E ratio 2025 * |
25x | P/E ratio 2026 * | 23.1x |
|---|---|---|---|---|---|
| Enterprise value | 216B 184B 172B 161B 297B 19,534B 325B 2,003B 777B 9,208B 809B 792B 33,594B | EV / Sales 2025 * |
5.94x | EV / Sales 2026 * | 5.7x |
| Free-Float |
99.85% | Yield 2025 * |
3.01% | Yield 2026 * | 3.19% |
Last Transcript: Amgen Inc.
| 1 day | +0.11% | ||
| 1 week | -3.68% | ||
| Current month | -8.02% | ||
| 1 month | -5.64% | ||
| 3 months | +14.96% | ||
| 6 months | +7.63% | ||
| Current year | +21.91% |
| 1 week | 312.38 |  | 323 |
| 1 month | 312.38 | | 346.38 |
| Current year | 257.05 | | 346.38 |
| 1 year | 253.3 | | 346.38 |
| 3 years | 211.71 | | 346.85 |
| 5 years | 198.64 | | 346.85 |
| 10 years | 133.64 | | 346.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 62 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 66 | 2019-12-31 |
Esteban Santos
COO | Chief Operating Officer | 58 | 2016-07-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 62 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 64 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 70 | 2011-12-31 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 5.08% | 135 M€ | +11.34% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.11% | -3.68% | +17.41% | +17.19% | 171B | |
| +1.80% | +1.70% | +30.21% | +182.67% | 920B | |
| +0.75% | +4.78% | +44.31% | +17.70% | 510B | |
| -0.29% | -1.22% | +28.81% | +35.46% | 395B | |
| -0.35% | +1.90% | +25.12% | +3.01% | 340B | |
| -1.12% | -1.09% | +28.43% | +17.93% | 278B | |
| -0.45% | -1.48% | +20.24% | +22.49% | 254B | |
| +1.30% | +0.58% | -1.67% | -10.09% | 249B | |
| +0.45% | +3.73% | -57.41% | -31.49% | 224B | |
| -2.28% | -0.68% | +31.08% | +36.20% | 149B | |
| Average | -0.01% | +0.45% | +16.65% | +29.11% | 349.14B | |
| Weighted average by Cap. | +0.42% | +1.07% | +22.26% | +57.74% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 36.33B 30.95B 28.91B 27.2B 50.08B 3,290B 54.71B 337B 131B 1,551B 136B 133B 5,659B | 36.9B 31.44B 29.37B 27.63B 50.87B 3,342B 55.57B 343B 133B 1,576B 138B 136B 5,748B |
| Net income | 7.34B 6.26B 5.84B 5.5B 10.12B 665B 11.06B 68.22B 26.46B 314B 27.56B 26.98B 1,144B | 7.37B 6.28B 5.87B 5.52B 10.17B 668B 11.11B 68.5B 26.57B 315B 27.67B 27.09B 1,149B |
| Net Debt | 44.57B 37.97B 35.47B 33.37B 61.44B 4,037B 67.12B 414B 161B 1,903B 167B 164B 6,942B | 39.37B 33.54B 31.33B 29.48B 54.27B 3,566B 59.29B 366B 142B 1,681B 148B 145B 6,133B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 317.74 $ | +0.11% | 2,247,321 |
| 25-12-11 | 317.38 $ | +0.63% | 2,455,125 |
| 25-12-10 | 315.38 $ | +0.49% | 3,071,492 |
| 25-12-09 | 313.85 $ | -2.30% | 2,925,118 |
| 25-12-08 | 321.23 $ | -2.63% | 3,510,785 |
Delayed Quote Nasdaq, December 12, 2025 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
